Indication: For the treatment of intraocular hypertension and chronic open-angle glaucoma
Pharmacology: Carteolol is a beta1 and beta2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Carteolol is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Carteolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. Carteolol reduces intraocular pressure with little or no effect on pupil size or accommodation in contrast to the miosis which cholinergic agents are known to produce.
Mechanism Of Action: The primary mechanism of the ocular hypotensive action of Carteolol in reducing intraocular pressure is most likely a decrease in aqueous humor production.
Drug Category: Sympatholytics; Antihypertensive Agents; Antiarrhythmic Agents; ATC:C07AA15; ATC:S01ED05
Interactions:
DrugBank: Interactions for Carteolol
Interactions for Carteolol:
Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because
of the potential for additive effects on systemic beta-blockade.
Close observation of the patient is recommended when a beta-blocker is administered to patients receiving
catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of
hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.
Chemical IUPAC Name: 5-(2-hydroxy-3-tert-butylamino-propoxy)-3,4-dihydro-1H-quinolin-2-one
